Trial Profile
A Phase Ib/II Clinical Study of BBI608 Administered in Combination With Immune Checkpoint Inhibitors to Adult Patients With Advanced Cancers
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 18 Oct 2023
Price :
$35
*
At a glance
- Drugs Ipilimumab (Primary) ; Napabucasin (Primary) ; Nivolumab (Primary) ; Pembrolizumab (Primary)
- Indications Cancer
- Focus Adverse reactions
- Sponsors Boston Biomedical; Sumitomo Dainippon Pharma Oncology; Sumitomo Pharma America
- 27 Apr 2021 Status changed from active, no longer recruiting to completed.
- 22 Jan 2021 Planned End Date changed from 1 Jun 2020 to 1 Jun 2021.
- 22 Jan 2021 Planned primary completion date changed from 1 Jun 2020 to 1 Jun 2021.